Results 181 to 190 of about 70,073 (274)

Outcomes for Patients With SPOP Mutated Castration-Resistant Prostate Cancer (CRPC) Treated With an Androgen Receptor Pathway Inhibitor (ARPI). [PDF]

Clin Genitourin Cancer
Park JJ, Howard LE, Fragkogianni S, George DJ, Armstrong AJ.   +4 more
europepmc   +1 more source

Predictive value of peripheral blood immune markers for castration-resistant prostate cancer development after endocrine therapy. [PDF]

Front Oncol
Li F, Cui L, Zhang G, Hao J.
europepmc   +1 more source

YM155 Inhibition of Survivin Enhances Carboplatin Efficacy in Metastatic Castration-Resistant Prostate Cancer. [PDF]

Pharmaceuticals (Basel)
Ruiz de Porras V, Bakht MK, Fernandez-Saorín M, Alcon C, Palomero L, Francisco-Rodon J, Figols M, Montero J, Conteduca V, Beltran H, Font A.   +10 more
europepmc   +1 more source

Correction: Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. [PDF]

Oncogene
Cherif C, Nguyen DT, Paris C, Le TK, Sefiane T, Carbuccia N, Finetti P, Chaffanet M, El Kaoutari A, Vernerey J, Fazli L, Gleave M, Manai M, Barthélémy P, Birnbaum D, Bertucci F, Taïeb D, Rocchi P.   +17 more
europepmc   +1 more source

Synergistic potential of sipuleucel-T in enhancing immunotherapy for metastatic castration-resistant prostate cancer. [PDF]

J Immunother Cancer
Rawat K, Punia V, Mathews P, McCoy S, Song W, Saeed MA, Pachynski RK.   +6 more
europepmc   +1 more source

Integrating NLP to Enhance Algorithmic Identification of Metastatic and Castration-Resistant Prostate Cancer in Large Claims-Based Studies. [PDF]

Cancer Med
Stock SR, Parrish JA, Burns MT, Janes JL, Waller J, De Hoedt AM, Ghate S, Kim J, Shui IM, Freedland SJ.   +9 more
europepmc   +1 more source

EpCAM-PSMA: Potential predictors of treatment outcomes for PSMA-targeted alpha therapies in metastatic castration-resistant prostate cancer. [PDF]

Mol Ther Oncol
Bakos G, Bauder-Wüst U, Landry J, Roscher M, Ramasz B, Bruchertseifer F, Morgenstern A, Kratochwil C, Beneš V, Benešová-Schäfer M.   +9 more
europepmc   +1 more source

Steroidogenesis inhibitor opevesostat (MK-5684) for metastatic castration-resistant prostate cancer: OMAHA-003 and OMAHA-004 trial designs. [PDF]

Future Oncol
Yu EY, Gratzke C, Burotto M, Zhang AY, Lévesque E, Ortega F, Peer A, Vile D, Chen ZH, Song Y, Schloss C, Todoric J, Garratt C, Poehlein C, Antonarakis ES, Fizazi K.   +15 more
europepmc   +1 more source

Phase Ib study of enzalutamide with venetoclax in patients with metastatic castration-resistant prostate cancer. [PDF]

Cancer Chemother Pharmacol
Perimbeti S, Jamroze A, Gopalakrishnan D, Jain R, Jiang C, Holleran JL, Parise RA, Bies R, Quinn D, Attwood K, Liu X, Green K, Kirk JS, Beumer JH, Tang DG, Chatta G.   +15 more
europepmc   +1 more source